Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Immunomodulatory effects of Vitamin D in multiple sclerosis.
The role of T cell apoptosis in nervous system autoimmunity.
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
Vitamin D intake and incidence of multiple sclerosis.
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
Treatment of acute transverse myelitis and its early complications.
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.
Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
Multiple sclerosis: an immune or neurodegenerative disorder?
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
Laquinimod in multiple sclerosis.
Treatment of neuromyelitis optica.
CNS myelin wrapping is driven by actin disassembly.
Imaging outcomes for trials of remyelination in multiple sclerosis.
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder.
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.

Pages